Svas Biosana S.p.a. · MIL:SVS
Svas Biosana — Spring Investor Conference – Banca Profilo 2025
16 slides from Svas Biosana's conference presentation, April 2025
Slide 1: Investor Presentation
Investor Presentation Spring Investor Conference – Banca Profilo April 2025 Strictly Private and Confidential
Slide 2: Shareholders’ Structure & Key People
Shareholders’ Structure & Key People Shareholders (1) Key People 21 Monte Free Float and Somma S.r.l. Others 43,86% (2) 30,91% SVAS Biosana S.p.A. 5,07% Umberto Perillo Andrea Efficace Chief Executive Officer Mark Medical CEO & Group CFO Agrinvest S.r.l. 0,93% (3) Danila Antonia Perillo Mr. Perillo
Slide 3: Group Overview
Group Overview SVAS Biosana Group (“SVAS”, the “Company” or the “Group”) is an Italian leading player in the medical devices and disposables sector, acting Svas Biosana «At a Glance» both as a manufacturer and as a distributor. Key Financial Highlights The Group was founded in Southern Italy in 1972
Slide 4: Group Overview: Geographical Presence and History
Group Overview Geographical Presence and History Warehouses and Offices Somma Vesuviana (NA) – 12.200 sqm: Chemical Microbiologic Division Division Site 1 (Via Trentola 7) Medical Devices in development Cosmetics Pharmaceutical Site 2 (Via Colle 104) Expertise Micro & Nanotechnology Bioenginee
Slide 5: Group Overview: Business Snapshot
Group Overview Legend Production & Sale Business Snapshot Distribution & Sale Company Activity Production Distribution Business €34.9m €8.2m €20.2m Mark €40.6m €18m Farmex Medical Svas Bormia Line(1) 28.6% 6.7% 16.6% Medical 33.3% 14.8% Incontinence Products Custom Packs & Specialist Disposables Adv
Slide 6: Production – Main products
Production – Main products Farmex Medical Adult Incontinence Aids Custom Pack Standard Dressings Cotton Wool Advanced Dressings Surgical Suction Infusion and Systems Drainage Devices Svas Biosana Investor Presentation April 2025 6
Slide 7: Distribution – Main products
Distribution – Main products Specialties Cardiac Surgery Orthopedics and Arthroscopy Drug Transfer Devices for Peritoneal Dyalisis Cardiopulmonary TAVI Orthopedic Arthroscopy Implants Devices Anesthesia Products Implants and Equipment Radiology & Imaging Cardiology Laparoscopic Advanced Hemostatic C
Slide 8: FY 2024 Sales Breakdown
Group Overview Fy 2024 Sales Breakdown By Activity By Geography By Customer Type Production Private 35% Customers FY 2024 Foreign Sales1 ~ 25% Countries FY 2024 FY FY 2024 2022 Sales¹ 49% Sales1 Italy Distribution 51% 65% Public Customers ~ 75% First-class Suppliers National Public Hospitals Public
Slide 9: Investment Highlights and Market Dynamics
Group Overview Investment Highlights and Market Dynamics 1. Rich and consolidated portfolio of products to satisfy chronic, 2. Qualified commercial structure and close relationship with medical operators medical and surgical healthcare needs generate additional value while creating high entry barrie
Slide 10: Financial Data
Financial Data Key Financial Highlights Millions of Euro Net Revenue Millions of Euro EBITDA 14,2 30,00% 118,3 120,2 14,00 € 120,00 € 11,9 25,00% 97,2 12,00 € 10,6 100,00 € 9,6 81,1 10,00 € 20,00% 76,6 80,00 € Millions of Euro 2020A 2021A 2022A 2023A H12024 8,00 € 15,00% 60,00 € 6,00 € Net Revenue 7
Slide 11: Annex: Group Structure
Annex Group Structure Absolute majority of shares owned by Umberto Perillo Free Float and 21 Monte Danila Antonia Svas Biosana Others Agrinvest S.r.l. Cofi Italia S.r.l. Belforte S.r.l. Board of Directors Somma S.r. 𝑙..( ) Perillo S.p.A. 43,86% 5,58% 5,07% 0,93% 8,19% 5,46% 30,91% Filippo…
Slide 12: H1 Consolidated Income Statement
Annex H1 Consolidated Income Statement 30/06/2023 % 30/06/2024 % Delta % Revenues from sales and service 54.939.038 100% 58.185.142 100% 3.246.104 6% External Costs 43.144.031 79% 44.226.766 76% 1.082.735 3% Added Value 11.795.007 21% 13.958.376 24% 2.163.369 18% Cost of labor (6.808.083) 12% (7.128
Slide 13: H1 Consolidated Balance Sheet
Annex H1 Consolidated Balance Sheet 31/12/2023 30/06/2024 Delta Net Intangible fixed assets 11.419.565 11.676.396 256.831 Net Tangible Fixed Assets 26.774.269 26.018.354 (755.915) Equity investments and other financial fixed assets 110.179 110.179 - Fixed Capital 38.304.013 37.804.929 (499.084) Inve
Slide 14: Consolidated Income Statement
Annex Consolidated Income Statement 31/12/2022 % 31/12/2023 % Delta % Revenues from sales and service 97.226.932 100,0% 118.283.990 100,0% 21.057.058 21,7% External Costs (74.943.464) 77,1% (93.635.659) 79,2% (18.692.195) 24,9% Added Value 22.283.468 22,9% 24.648.331 20,8% 2.364.863 10,6% Cost of la
Slide 15: Consolidated Balance Sheet
Annex Consolidated Balance Sheet 31/12/2022 31/12/2023 Delta Net Intangible fixed assets 11.023.670 11.419.565 395.895 Net Tangible Fixed Assets 26.209.159 26.774.269 565.110 Equity investments and other financial fixed assets 229.980 110.179 (119.801) Fixed Capital 37.462.809 38.304.013 841.204 Inv
Slide 16: Legal Disclaimer
Legal Disclaimer For the purposes of this disclaimer, this presentation (the “Presentation”) comprises the attached slides and any materials distributed at, or in connection with, the Presentation. The Presentation has been prepared bY Svas Biosana S.p.A. (the “Company”) solely for information and d
Svas Biosana — Spring Investor Conference – Banca Profilo 2025 on 6ix